vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and FIRST COMMONWEALTH FINANCIAL CORP (FCF). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $133.7M, roughly 1.4× FIRST COMMONWEALTH FINANCIAL CORP). FIRST COMMONWEALTH FINANCIAL CORP runs the higher net margin — 28.1% vs 13.3%, a 14.7% gap on every dollar of revenue. On growth, FIRST COMMONWEALTH FINANCIAL CORP posted the faster year-over-year revenue change (13.0% vs -1.8%). Over the past eight quarters, FIRST COMMONWEALTH FINANCIAL CORP's revenue compounded faster (5.5% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
First Commonwealth Financial Corp is a Pennsylvania-based regional financial services holding company. It offers consumer and commercial banking products, loans, wealth management, and insurance services for individuals, small and mid-sized enterprises across central and western Pennsylvania and Ohio.
AMPH vs FCF — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $133.7M |
| Net Profit | $24.4M | $37.5M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | — |
| Net Margin | 13.3% | 28.1% |
| Revenue YoY | -1.8% | 13.0% |
| Net Profit YoY | -35.7% | -16.3% |
| EPS (diluted) | $0.51 | $0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $133.7M | ||
| Q4 25 | $183.1M | $137.9M | ||
| Q3 25 | $191.8M | $136.0M | ||
| Q2 25 | $174.4M | $131.0M | ||
| Q1 25 | $170.5M | $118.0M | ||
| Q4 24 | $186.5M | $120.4M | ||
| Q3 24 | $191.2M | $121.2M | ||
| Q2 24 | $182.4M | $120.2M |
| Q1 26 | — | $37.5M | ||
| Q4 25 | $24.4M | $44.9M | ||
| Q3 25 | $17.4M | $41.3M | ||
| Q2 25 | $31.0M | $33.4M | ||
| Q1 25 | $25.3M | $32.7M | ||
| Q4 24 | $38.0M | $35.8M | ||
| Q3 24 | $40.4M | $32.1M | ||
| Q2 24 | $37.9M | $37.1M |
| Q1 26 | — | — | ||
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 19.4% | 40.9% | ||
| Q3 25 | 13.2% | 38.1% | ||
| Q2 25 | 24.2% | 32.1% | ||
| Q1 25 | 21.9% | 34.8% | ||
| Q4 24 | 24.2% | 37.1% | ||
| Q3 24 | 29.8% | 33.4% | ||
| Q2 24 | 30.3% | 38.7% |
| Q1 26 | — | 28.1% | ||
| Q4 25 | 13.3% | 32.5% | ||
| Q3 25 | 9.0% | 30.4% | ||
| Q2 25 | 17.8% | 25.5% | ||
| Q1 25 | 14.8% | 27.7% | ||
| Q4 24 | 20.4% | 29.8% | ||
| Q3 24 | 21.1% | 26.5% | ||
| Q2 24 | 20.8% | 30.9% |
| Q1 26 | — | $0.37 | ||
| Q4 25 | $0.51 | $0.44 | ||
| Q3 25 | $0.37 | $0.39 | ||
| Q2 25 | $0.64 | $0.32 | ||
| Q1 25 | $0.51 | $0.32 | ||
| Q4 24 | $0.74 | $0.35 | ||
| Q3 24 | $0.78 | $0.31 | ||
| Q2 24 | $0.73 | $0.36 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | — |
| Total DebtLower is stronger | $608.7M | $154.9M |
| Stockholders' EquityBook value | $788.8M | $1.6B |
| Total Assets | $1.6B | $12.3B |
| Debt / EquityLower = less leverage | 0.77× | 0.10× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | — | ||
| Q2 25 | $231.8M | — | ||
| Q1 25 | $236.9M | — | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | — | ||
| Q2 24 | $217.8M | — |
| Q1 26 | — | $154.9M | ||
| Q4 25 | $608.7M | $261.7M | ||
| Q3 25 | $608.6M | $262.1M | ||
| Q2 25 | $607.7M | $262.4M | ||
| Q1 25 | $603.9M | $262.7M | ||
| Q4 24 | $601.6M | $263.0M | ||
| Q3 24 | $596.4M | $136.3M | ||
| Q2 24 | $586.9M | $136.6M |
| Q1 26 | — | $1.6B | ||
| Q4 25 | $788.8M | $1.6B | ||
| Q3 25 | $776.7M | $1.5B | ||
| Q2 25 | $757.5M | $1.5B | ||
| Q1 25 | $751.3M | $1.4B | ||
| Q4 24 | $732.3M | $1.4B | ||
| Q3 24 | $727.7M | $1.4B | ||
| Q2 24 | $713.3M | $1.4B |
| Q1 26 | — | $12.3B | ||
| Q4 25 | $1.6B | $12.3B | ||
| Q3 25 | $1.7B | $12.3B | ||
| Q2 25 | $1.6B | $12.2B | ||
| Q1 25 | $1.6B | $11.8B | ||
| Q4 24 | $1.6B | $11.6B | ||
| Q3 24 | $1.5B | $12.0B | ||
| Q2 24 | $1.5B | $11.6B |
| Q1 26 | — | 0.10× | ||
| Q4 25 | 0.77× | 0.17× | ||
| Q3 25 | 0.78× | 0.17× | ||
| Q2 25 | 0.80× | 0.17× | ||
| Q1 25 | 0.80× | 0.18× | ||
| Q4 24 | 0.82× | 0.19× | ||
| Q3 24 | 0.82× | 0.10× | ||
| Q2 24 | 0.82× | 0.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | — |
| Free Cash FlowOCF − Capex | $24.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 4.5% | — |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $32.9M | $187.5M | ||
| Q3 25 | $52.6M | $49.5M | ||
| Q2 25 | $35.6M | $30.4M | ||
| Q1 25 | $35.1M | $55.9M | ||
| Q4 24 | $29.0M | $129.5M | ||
| Q3 24 | $60.0M | $53.6M | ||
| Q2 24 | $69.1M | $22.7M |
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $171.5M | ||
| Q3 25 | $47.2M | — | ||
| Q2 25 | $25.0M | — | ||
| Q1 25 | $24.4M | — | ||
| Q4 24 | $16.6M | $113.9M | ||
| Q3 24 | $46.2M | — | ||
| Q2 24 | $63.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 124.3% | ||
| Q3 25 | 24.6% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.3% | — | ||
| Q4 24 | 8.9% | 94.6% | ||
| Q3 24 | 24.1% | — | ||
| Q2 24 | 34.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 11.7% | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 6.3% | — | ||
| Q4 24 | 6.7% | 12.9% | ||
| Q3 24 | 7.2% | — | ||
| Q2 24 | 3.3% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | 4.18× | ||
| Q3 25 | 3.03× | 1.20× | ||
| Q2 25 | 1.15× | 0.91× | ||
| Q1 25 | 1.39× | 1.71× | ||
| Q4 24 | 0.76× | 3.61× | ||
| Q3 24 | 1.48× | 1.67× | ||
| Q2 24 | 1.82× | 0.61× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
FCF
Segment breakdown not available.
